-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In February 2021, BIO, Informa Pharma Intelligence and QLS jointly released the report "Clinical Development Success Rates and Contributing Factors 2011-2020".
The innovative drugs of domestic companies are mainly me-too/follow drugs, and the probability of success is relatively high.
The good news is that Biotech has set a new example.
In addition to discontinued research drugs, there are also some marketed drugs, especially those with conditional approval, that need confirmatory clinical evidence of definite benefits to prove themselves.
It should be pointed out that the transparency of innovative drug development, clinical progress and test results of domestic pharmaceutical companies still needs to be strengthened.
Don't make excuses for failure, only find evidence for success.
It is true that the development of innovative drugs is inseparable from financial support.
The clinical value of innovative drugs is crucial for the success of innovative drugs.
For the treatment drugs that have changed clinical practice and are included in the guidelines, even the me-too/follow benchmark drugs, more latecomers still choose to go head-to-head with previous therapies.
After PD-1 drugs are "involved", globalization has become a new goal.
For Fast follow, the benchmark drug has not yet completed the clinical concept verification, so what about its own Better/Best? Me similar may be the best destination.
Eli Lilly’s new-generation KRAS inhibitor LY3537982 has increased cell activity by at least 10 times, and its target occupancy rate has increased from 70% to more than 90%.
Regardless of whether it is for the purpose of clinical value or for source innovation, it is essentially the "inner strength method" of innovative drug development centered on patients.
The success of innovative drugs must come from designing from the source of real clinical needs, and it should also be the most basic "successful way" rule.
Objective and fair, seeking truth from facts, and down-to-earth through the inevitable stage of China's innovative drugs, the future of innovative drugs can be sunny and blue.
